Cargando…

Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib

BACKGROUND: Rechallenge with imatinib is an option in advanced gastrointestinal stromal tumor (GIST) patients following progression with standard tyrosine-kinase inhibitors (TKIs), imatinib, sunitinib and regorafenib. We retrospectively collected data from metastatic Italian GIST patients treated wi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vincenzi, Bruno, Nannini, Margherita, Badalamenti, Giuseppe, Grignani, Giovanni, Fumagalli, Elena, Gasperoni, Silvia, D’Ambrosio, Lorenzo, Incorvaia, Lorena, Stellato, Marco, Spalato Ceruso, Mariella, Napolitano, Andrea, Valeri, Sergio, Santini, Daniele, Tonini, Giuseppe, Casali, Paolo Giovanni, Dei Tos, Angelo Paolo, Pantaleo, Maria Abbondanza
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6116078/ https://www.ncbi.nlm.nih.gov/pubmed/30181783 http://dx.doi.org/10.1177/1758835918794623

Ejemplares similares

Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: a retrospective analysis
por: Vincenzi, Bruno, et al.
Publicado: (2015)

Impact of Rechallenge with Imatinib in Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib
por: Sawaki, Akira, et al.
Publicado: (2014)

Personalization of regorafenib treatment in metastatic gastrointestinal stromal tumours in real-life clinical practice
por: Nannini, Margherita, et al.
Publicado: (2017)

Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study
por: Vincenzi, Bruno, et al.
Publicado: (2022)

Imatinib Mesylate-Induced Erythema Multiforme: Recurrence after Rechallenge with 200 mg/day Imatinib
por: Lee, Min Kyung, et al.
Publicado: (2015)

Recent Advances in Desmoid Tumor Therapy
por: Napolitano, Andrea, et al.
Publicado: (2020)

A mutation-based radiomics signature predicts response to imatinib in Gastrointestinal Stromal Tumors (GIST)
por: Cappello, Giovanni, et al.
Publicado: (2023)

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumor after failure with imatinib and sunitinib treatment: A meta-analysis
por: Zhang, Zhenan, et al.
Publicado: (2017)

Familial adenomatosis polyposis–related desmoid tumours treated with low-dose chemotherapy: results from an international, multi-institutional, retrospective analysis
por: Napolitano, Andrea, et al.
Publicado: (2020)

Successful Rechallenge with Imatinib in a Patient with Chronic Myeloid Leukemia Who Previously Experienced Imatinib Mesylate Induced Pneumonitis
por: Go, Seong Woo, et al.
Publicado: (2013)

Standard versus personalized schedule of regorafenib in metastatic gastrointestinal stromal tumors: a retrospective, multicenter, real-world study
por: Nannini, M., et al.
Publicado: (2021)

Evaluation of nilotinib in advanced GIST previously treated with imatinib and sunitinib
por: Cauchi, C., et al.
Publicado: (2011)

Type and Gene Location of KIT Mutations Predict Progression-Free Survival to First-Line Imatinib in Gastrointestinal Stromal Tumors: A Look into the Exon
por: Incorvaia, Lorena, et al.
Publicado: (2021)

Adverse reactions of sorafenib, sunitinib, and imatinib in treating digestive system tumors
por: Fu, Yali, et al.
Publicado: (2018)

Lack of Correlation Between Liver Tests Abnormalities and Trabectedin Efficacy in the Treatment of Soft Tissue Sarcoma: a Retrospective Study
por: Vincenzi, Bruno, et al.
Publicado: (2015)

New frontiers in the medical management of gastrointestinal stromal tumours
por: Mazzocca, Alessandro, et al.
Publicado: (2019)

Efficacy and Safety of Regorafenib in Korean Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib: A Multicenter Study Based on the Management Access Program
por: Son, Myoung Kyun, et al.
Publicado: (2017)

Regorafenib treatment outcome for Taiwanese patients with metastatic gastrointestinal stromal tumors after failure of imatinib and sunitinib: A prospective, non-randomized, single-center study
por: Hu, Chia-Hsiang, et al.
Publicado: (2020)

Impact of adjuvant imatinib on bone and muscle density in patients with resected gastrointestinal stromal tumors
por: Fulgenzi, Claudia Angela Maria, et al.
Publicado: (2022)

Rechallenge therapy and treatment holiday: different strategies in management of metastatic colorectal cancer
por: Tonini, Giuseppe, et al.
Publicado: (2013)

Response to imatinib in villonodular pigmented synovitis (PVNS) resistant to nilotinib
por: Stacchiotti, Silvia, et al.
Publicado: (2013)

Surgery after treatment with imatinib and/or sunitinib in patients with metastasized gastrointestinal stromal tumors: is it worthwhile?
por: Tielen, Ronald, et al.
Publicado: (2012)

Human equilibrative nucleoside transporter 1 gene expression is associated with gemcitabine efficacy in advanced leiomyosarcoma and angiosarcoma
por: Vincenzi, Bruno, et al.
Publicado: (2017)

Sunitinib versus imatinib dose escalation after failure of imatinib standard dose in patients with advanced Gastrointestinal stromal tumors – a real-world multi-center study
por: Huang, Shaoqing, et al.
Publicado: (2023)

A favorable outcome of advanced dermatofibrosarcoma protuberans under treatment with sunitinib after imatinib failure
por: Xiao, Wei, et al.
Publicado: (2018)

The pharmacogenetics of imatinib
por: Dulucq, Stéphanie, et al.
Publicado: (2010)

Primary imatinib failure rescued by dasatinib and maintained by reintroduction of imatinib
por: Kumar, Rajiv, et al.
Publicado: (2017)

Imatinib in combination with phosphoinositol kinase inhibitor buparlisib in patients with gastrointestinal stromal tumour who failed prior therapy with imatinib and sunitinib: a Phase 1b, multicentre study
por: Gelderblom, Hans, et al.
Publicado: (2020)

Successful treatment of gemcitabine-induced acute interstitial pneumonia with imatinib mesylate: a case report
por: Fenocchio, Elisabetta, et al.
Publicado: (2016)

Idiopathic hypereosinophilic syndrome presenting with severe vasculitis successfully treated with imatinib
por: Fraticelli, Paolo, et al.
Publicado: (2016)

Imatinib, sunitinib and pazopanib: From flat‐fixed dosing towards a pharmacokinetically guided personalized dose
por: Westerdijk, Kim, et al.
Publicado: (2020)

Debulking of Advanced Gastrointestinal Stromal Tumor With Peritoneal Carcinomatosis Refractory to Imatinib and Sunitinib: A Case Report
por: Rave, Talia E., et al.
Publicado: (2021)

Response to imatinib rechallenge in a patient with a recurrent gastrointestinal stromal tumor after adjuvant therapy: a case report
por: Kang, Yoon-Koo
Publicado: (2011)

Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to imatinib
por: Joensuu, Heikki, et al.
Publicado: (2017)

Gain of FGF4 is a frequent event in KIT/PDGFRA/SDH/RAS‐P WT GIST
por: Urbini, Milena, et al.
Publicado: (2019)

Response to: Successful afatinib rechallenge in a patient with non‐small cell lung cancer harboring EGFR G719C and S768I mutations
por: Citarella, Fabrizio, et al.
Publicado: (2021)

Guideline-Based Follow-Up Outcomes in Patients With Gastrointestinal Stromal Tumor With Low Risk of Recurrence: A Report From the Italian Sarcoma Group
por: D’Ambrosio, Lorenzo, et al.
Publicado: (2023)

Exploiting the promiscuity of imatinib
por: Lee, Shun J, et al.
Publicado: (2009)

Imatinib-induced pancreatitis
por: Varma, Mahesh R., et al.
Publicado: (2010)

Reintroduction of Imatinib in GIST
por: Reid, T.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_uod943be01msu5hmvh585lc34u